Bayer is set to present new oncology data at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17, 2024.
A major focus will be on prostate cancer, with late-breaking data on darolutamide and radium-223. Bayer’s goal is to enhance prostate cancer care through innovative treatments that can delay disease progression and extend survival at various stages of the disease. These options aim to help physicians personalize treatment plans to meet individual patient needs while preserving their quality of life.
Key highlights include:
- Darolutamide: Bayer will present a late-breaking abstract on the ARANOTE study, a pivotal Phase III trial assessing the efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide, marketed as Nubeqa®, is already approved for use with ADT and docetaxel in over 80 markets and for non-metastatic castration-resistant prostate cancer (nmCRPC) in more than 85 countries.
- Radium-223: Data from the EORTC-sponsored Phase III PEACE-III study will be featured in a “Presidential Symposium I: Practice-changing trials”. This study compares enzalutamide alone to a combination of enzalutamide and radium-223 dichloride in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC). Radium-223, marketed as Xofigo®, is approved in over 50 countries for treating mCRPC with symptomatic bone metastases and no known visceral disease.
- NSCLC Treatment: Bayer will present the design of the Phase III SOHO-02 trial, which is evaluating BAY 2927088, an oral tyrosine kinase inhibitor, compared to standard care for first-line treatment of HER2-activating mutation-positive non-small cell lung cancer (NSCLC). This study follows data from the SOHO-01 study, which will be discussed at the 2024 World Conference on Lung Cancer (WCLC 2024).
- TRK Fusion Cancer: Updated analyses from the SCOUT and NAVIGATE studies will be shared, focusing on larotrectinib’s efficacy and safety as a first-line treatment for TRK fusion cancer in children and adults, respectively. Larotrectinib, branded as Vitrakvi®, is approved in over 45 countries for neurotrophic TRK fusion-positive solid tumors.
Bayer’s presentations at ESMO 2024 will showcase the company’s ongoing commitment to advancing cancer treatment through cutting-edge research and innovative therapies.
